Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2026-09-11 19:51:38 ET · period of report 2026-09-09 · accession 0001193125-26-389550 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-11 19:51 | 2026-09-09 | MGX | Reid Laurence | Dir | P - Purchase | $1.17 | +20.0K | 20.0K | New | +$23.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-09 | P | A | 19,883 | $1.17 | 19,883 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2026-09-09 | P | A | 117 | $1.18 | 20,000 | D | — | — |